Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers
Given the results of the GETUG 14 randomized trial presented at ASCO 2016, should all men with intermediate-risk prostate cancer receiving dose-escalated radiotherapy receive concurrent ADT?
In this abstract the 5-year probability of survival without clinical/biochemical relapse was significantly improved with ADT.
Answer from: Radiation Oncologist at Academic Institution
Neither the GETUG 14 or EORTC 22991 study just published in JCO are mature enough yet to fully answer the question based on endpoints of death from PC and/or overall survival.The third study looking at this is RTOG 0815 which also is not mature yet.It is likely that men with favorable int risk can b...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
High dose radiation does not improve overall survival; ADT does improve OS . Why go beyond 7560cGy? It just dries up the prostate and decreases ejaculate.